{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:32:55Z","timestamp":1793795575143,"version":"4.6.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.omtm.2025.101568","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T22:28:31Z","timestamp":1755556111000},"page":"101568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 study"],"prefix":"10.1016","volume":"33","author":[{"given":"Robert","family":"Klamroth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Recht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel S.","family":"Key","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Miesbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Pipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radoslaw","family":"Kaczmarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglass","family":"Drelich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6203-3946","authenticated-orcid":false,"given":"Sandra","family":"Le Quellec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Monahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Galante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"van der Valk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Tarrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2025.101568_bib1","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101568_bib2","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/S2352-3026(24)00006-1","article-title":"Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial","volume":"11","author":"Coppens","year":"2024","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.omtm.2025.101568_bib3","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2302982","article-title":"Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B","volume":"391","author":"Cuker","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101568_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/v13010101","article-title":"Completion of the AAV Structural Atlas: Serotype Capsid Structures Reveals Clade-Specific Features","volume":"13","author":"Mietzsch","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.omtm.2025.101568_bib5","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1128\/JVI.73.2.939-947.1999","article-title":"Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses","volume":"73","author":"Bantel-Schaal","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.omtm.2025.101568_bib6","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1128\/JVI.00867-13","article-title":"Structural insights into adeno-associated virus serotype 5","volume":"87","author":"Govindasamy","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.omtm.2025.101568_bib7","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jtha.2023.12.005","article-title":"Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia","volume":"22","author":"Pierce","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.omtm.2025.101568_bib8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.omtm.2022.02.011","article-title":"Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations","volume":"25","author":"Mendell","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101568_bib9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1089\/hum.2021.243","article-title":"Higher Seroprevalence of Anti-Adeno-Associated Viral Vector Neutralizing Antibodies Among Racial Minorities in the United States","volume":"33","author":"Khatri","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2025.101568_bib10","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/hum.2021.287","article-title":"Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A","volume":"33","author":"Klamroth","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2025.101568_bib11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/gt.2011.90","article-title":"Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia","volume":"19","author":"Li","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2025.101568_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ymthe.2005.08.017","article-title":"Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates","volume":"13","author":"Gao","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101568_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2019.05.014","article-title":"Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors","volume":"14","author":"Kruzik","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101568_bib14","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.omtm.2025.101568_bib15","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.ymthe.2024.05.033","article-title":"Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A","volume":"32","author":"Long","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101568_bib16","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1208\/s12248-021-00628-3","article-title":"Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays","volume":"23","author":"Gorovits","year":"2021","journal-title":"AAPS J."},{"key":"10.1016\/j.omtm.2025.101568_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1208\/s12248-019-0403-1","article-title":"Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays","volume":"22","author":"Gorovits","year":"2020","journal-title":"AAPS J."},{"key":"10.1016\/j.omtm.2025.101568_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101126","article-title":"A sensitive AAV transduction inhibition assay assists evaluation of critical factors for detection and concordance of pre-existing antibodies","volume":"31","author":"Pan","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101568_bib19","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1002\/jmv.23818","article-title":"The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals","volume":"86","author":"Mimuro","year":"2014","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.omtm.2025.101568_bib20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41434-024-00441-5","article-title":"Multicenter assessment and longitudinal study of the prevalence of antibodies and related adaptive immune responses to AAV in adult males with hemophilia","volume":"31","author":"Pabinger","year":"2024","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2025.101568_bib21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/rth2.12177","article-title":"Adenovirus-associated antibodies in UK cohort of hemophilia patients: A seroprevalence study of the presence of adenovirus-associated virus vector-serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia A","volume":"3","author":"Stanford","year":"2019","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.omtm.2025.101568_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12020318","article-title":"The Evolution of the Safety of Plasma Products from Pathogen Transmission-A Continuing Narrative","volume":"12","author":"Farrugia","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.omtm.2025.101568_bib23","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1537-2995.2012.03907.x","article-title":"Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening","volume":"53","author":"Soucie","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.omtm.2025.101568_bib24","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41434-022-00353-2","article-title":"Clinical enrollment assay to detect preexisting neutralizing antibodies to AAV6 with demonstrated transgene expression in gene therapy trials","volume":"30","author":"Cao","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2025.101568_bib25","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.omtm.2025.101568_bib26","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/gt.2014.103","article-title":"AAVrh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy","volume":"22","author":"Thwaite","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2025.101568_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101273","article-title":"Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies","volume":"32","author":"Chhabra","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101568_bib28","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2025.101568_bib29","series-title":"Prevalence and Affinity\/avidity Assessment of Pre-existing NABs against AAV2, 5 and 8 Analyzed in the Serum of 300 Healthy Donors","author":"Majowicz","year":"2020"},{"key":"10.1016\/j.omtm.2025.101568_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00391-17","article-title":"Adeno-associated Virus (AAV) Serotypes Have Distinctive Interactions with Domains of the Cellular AAV Receptor","volume":"91","author":"Pillay","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.omtm.2025.101568_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/v12111326","article-title":"The Structure of an AAV5-AAVR Complex at 2.5 \u00c5 Resolution: Implications for Cellular Entry and Immune Neutralization of AAV Gene Therapy Vectors","volume":"12","author":"Silveria","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.omtm.2025.101568_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1116896","article-title":"Adeno-associated virus receptor complexes and implications for adeno-associated virus immune neutralization","volume":"14","author":"Large","year":"2023","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.omtm.2025.101568_bib33","series-title":"Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins - Scientific Guideline. EMEA\/CHMP\/BMWP\/42832\/2005","year":"2017"},{"key":"10.1016\/j.omtm.2025.101568_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omtm.2019.05.009","article-title":"Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs","volume":"14","author":"Majowicz","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101568_bib35","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.omtm.2018.08.001","article-title":"AAV-8 and AAV-9 Vectors Cooperate with Serum Proteins Differently Than AAV-1 and AAV-6","volume":"10","author":"Denard","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101568_bib36","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.omtm.2019.03.006","article-title":"The Impact of Pre-existing Immunity on the Non-clinical Pharmacodynamics of AAV5-Based Gene Therapy","volume":"13","author":"Long","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101568_bib37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/hgtb.2015.037","article-title":"Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in vitro reporter system","volume":"26","author":"Meliani","year":"2015","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.omtm.2025.101568_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101217","article-title":"Preexisting antibody assays for gene therapy: Considerations on patient selection cutoffs and companion diagnostic requirements","volume":"32","author":"Braun","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101568_bib39","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101568_bib40","first-page":"1","article-title":"Correct Use of Percent Coefficient of Variation (%CV) Formula for Log-Transformed Data","volume":"6","author":"Canchola","year":"2017","journal-title":"MOJ Proteom. Bioinform."}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125001639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125001639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T15:21:50Z","timestamp":1762615310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050125001639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2329050125001639"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101568","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 study","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101568"}}